<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261494</url>
  </required_header>
  <id_info>
    <org_study_id>GFT505-210-5</org_study_id>
    <secondary_id>2010-021986-60</secondary_id>
    <nct_id>NCT01261494</nct_id>
  </id_info>
  <brief_title>Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with
      GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose.

      And to assess the tolerability and safety of once-a-day administrations of oral doses of
      GFT505 for 12 weeks in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per patient is 16-20 weeks maximum and is conducted as follows :

        -  Run-in period: 2 weeks or 6 weeks for patients under fibrate treatment at screening (4
           weeks fibrate wash-out + 2 weeks placebo run-in);

        -  Treatment period: 12 weeks;

        -  Follow-up period: 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate after 12 weeks of oral administration of double blind treatment the change from baseline in HbA1c level achieved with GFT505 80mg versus placebo. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the changes from baseline to end of treatment in OGTT parameters. Evaluation will be made prior the first treatment intake and 12 weeks after the first treatment intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the changes from baseline to end of treatment in fasting plasma Glucose. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance Index [fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR)]</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the changes from baseline to end of treatment in insulin resistance index. Evaluation will be made during the selection period, prior any drug intake, and 4, 8, 12 weeks after the first treatment intake as well as 2 weeks after the last treatment intake (follow up period).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GFT505 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFT505 80mg</intervention_name>
    <description>hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast</description>
    <arm_group_label>GFT505 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>hard gelatin capsules,oral administration,4 capsules per day before breakfast</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or post-menopausal female (defined as &gt;12 months since last menstrual period) or
             surgical menopause. If hormonal replacement therapy, it should be stable at least for
             6 months prior to screening.

          -  Body Mass Index ≥27 and ≤45 kg/m².

          -  Drug-Naive patients with type 2 diabetes mellitus (non insulin dependent diabetes).
             Patients should not be treated by insulin or other diabetes medication for the last 3
             months prior to screening. Patients treated for less than 4 weeks with insulin may be
             included in the study.

          -  HbA1c ≥ 7.0% and &lt;9.5%.

          -  Antibody glutamate decarboxylase acid (Anti-GAD) negative for patients aged less than
             40 years.

        Exclusion Criteria:

          -  Type I Diabetes Mellitus.

          -  Blood Pressure &gt; 160 / 95 mmHg.

          -  Lipid-lowering drugs such as fibrates.

          -  Fasting Plasma Glucose (FPG) ≥ 240 mg/dL.

          -  Triglycerides (TG) &gt; 400 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy HANF, Development Director</last_name>
    <role>Study Director</role>
    <affiliation>Genfit, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand CARIOU, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Nantes, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site n°12</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°11</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°22</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°21</name>
      <address>
        <city>Riga</city>
        <zip>LV 1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°23</name>
      <address>
        <city>Valmiera</city>
        <zip>LV4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°33</name>
      <address>
        <city>Bitola</city>
        <zip>7000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°31</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°32</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°41</name>
      <address>
        <city>Balti</city>
        <zip>3112</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°42</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°43</name>
      <address>
        <city>Chisinau</city>
        <zip>2068</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°72</name>
      <address>
        <city>Oradea</city>
        <state>Bihor County</state>
        <zip>410167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°66</name>
      <address>
        <city>Buzau</city>
        <state>Buzau County</state>
        <zip>120203</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°64</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj County</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°65</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures County</state>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°63</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures County</state>
        <zip>540098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°62</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures County</state>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°71</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova County</state>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°70</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova County</state>
        <zip>100342</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°61</name>
      <address>
        <city>Sibiu</city>
        <state>Sibiu County</state>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°67</name>
      <address>
        <city>Bucharest</city>
        <zip>020045</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°69</name>
      <address>
        <city>Bucharest</city>
        <zip>020045</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°68</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°52</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°53</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°56</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°54</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site n°51</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Latvia</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>July 12, 2011</last_update_submitted>
  <last_update_submitted_qc>July 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Product Development Department</name_title>
    <organization>Genfit</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>PPARs</keyword>
  <keyword>OGTT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

